Charles C. Wykoff
NEW ORLEANS — At 6 months, the HULK phase 1/2 trial demonstrated visual acuity benefit for all patients enrolled and a greater benefit for treatment-naïve eyes, Charles C. Wykoff, MD, said at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting.
The objective of the trial was to evaluate the safety and efficacy of 4 mg Zuprata (triamcinolone acetonide injectable suspension, Clearside Biomedical) administered to the suprachoroidal space alone or in conjunction with 2 mg intravitreal Eylea (aflibercept, Regeneron) for diabetic macular edema.
“A
Uncategorized